2Sharma K, Ziyadeh FN, Alzahabi B, et al. Increased renal production of transforming growth factor-betal in patients with type Ⅱ diabetes.Diabetes, 1997, 46(5): 854 - 859.
3Ziyadeh FN, Han DC. Involvement of transforming growthfactor-beta and its receptors in the pathogenesis of diabetic nephrology. Kidney Int,1997,52 (Suppl 60):s7-s11.
4Mogeuse CE.Predication of clinical diabetic nephropathy in patients,Diabetes,1990,39(3):761.
5Smith KG, Isbel NM, Catton MG, et al. Suppression of the hu moral immune response by mycophenolate mofetil. Nephrol Dial Transplant, 1998,13 : 160-164.
6Cattran DC. Mycophenolate mofetil and cyclosporine therapy in membranous nephropathy. Semin Nephrol, 2003,23 : 272-277.
7Romerro F, Rodriguez hurbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int, 1999,55 :945-955.
8Jayne D. Non-transplant uses of mycophenolate mofetil. CurrOpin Nephrol Hypertens, 1999,8:563-567.
9Badid C, Vincent M, MCgregor B, et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen deposition in rat remnant kidney. Kidney Int, 2000 : 58 : 51-61.
10Hauser IA, RendersL, Merkel C, et al. Mycophenolate mofetil, but not cyclosporine Aor FK506,inhibits rat mesangial cell proliferation in vitro. J Am SOC Nephrol, 1997,9:469-470.
